UB Paderborn / Katalog / Suche / in CDI

1 – 21 von 21

Sortiert nach

Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax

Leukemia & lymphoma, 2023-03, Vol.64 (4), p.897-899

2023

Link zum Volltext

Verfügbarkeit prüfen

Donor derived leukemia in allogeneic transplantation

Leukemia & lymphoma, 2021-10, Vol.62 (12), p.2823-2830

2021

Link zum Volltext

Verfügbarkeit prüfen

Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib

Leukemia & lymphoma, 2024-03, Vol.65 (3), p.372-6

2024

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement

Leukemia & lymphoma, 2020-07, Vol.61 (8), p.2020-2023

2020

Link zum Volltext

Verfügbarkeit prüfen

Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy

Leukemia & lymphoma, 2020-12, Vol.61 (14), p.3532-3533

2020

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation

Leukemia & lymphoma, 2022-05, Vol.63 (5), p.1220-1226

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665

Leukemia & lymphoma, 2016-10, Vol.57 (10), p.2298-2306

2016

Link zum Volltext

Verfügbarkeit prüfen

WT1 -mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens

Leukemia & lymphoma, 2023-11, Vol.64 (11), p.1811-1821

2023

Link zum Volltext

Verfügbarkeit prüfen

Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors

Leukemia & lymphoma, 2023-01, Vol.64 (1), p.188-196

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

Leukemia & lymphoma, 2022-12, Vol.63 (13), p.3232-3236

2022

Link zum Volltext

Verfügbarkeit prüfen

Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia

Leukemia & lymphoma, 2016-09, Vol.57 (9), p.2100-2108

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of AR-42 and decitabine in acute myeloid leukemia

Leukemia & lymphoma, 2020-05, Vol.61 (6), p.1484-1492

2020

Link zum Volltext

Verfügbarkeit prüfen

Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study

Leukemia & lymphoma, 2024-04, p.1-9

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia

Leukemia & lymphoma, 2014-06, Vol.55 (6), p.1304-1308

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia

Leukemia & lymphoma, 2013-09, Vol.54 (9), p.1996-2002

2013

Link zum Volltext

Verfügbarkeit prüfen

Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101

Leukemia & lymphoma, 2013-12, Vol.54 (12), p.2654-2659

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

Leukemia & lymphoma, 2014-06, Vol.55 (6), p.1332-1336

2014

Link zum Volltext

Verfügbarkeit prüfen

Chronic lymphocytic leukemia patients with high-risk genomic features have inferior outcome on successive CALGB trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101

Leukemia & lymphoma, 2013-05, Vol.54 (12)

2013

Link zum Volltext

Verfügbarkeit prüfen

Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study

Leukemia & lymphoma, 2012-09, Vol.53 (9), p.1743-1748

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Dose Escalation of the Heat Shock Protein Inhibitor 17-AAG in Combination with Bortezomib in Relapsed or Refractory Acute Myeloid Leukemia

Leukemia & lymphoma, 2013-01, Vol.54 (9)

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieLeukemia & Lymphoma

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Kollektion

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax

Donor derived leukemia in allogeneic transplantation

Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib

The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement

Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy

Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation

Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665

WT1 -mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens

Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia

Phase I study of AR-42 and decitabine in acute myeloid leukemia

Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study

High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy

Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia

Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia

Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

Chronic lymphocytic leukemia patients with high-risk genomic features have inferior outcome on successive CALGB trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101

Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study

Pharmacokinetics and Dose Escalation of the Heat Shock Protein Inhibitor 17-AAG in Combination with Bortezomib in Relapsed or Refractory Acute Myeloid Leukemia

Aktive Filter

Suchergebnisse filtern